Feasibility analysis and application of ovarian tissue oocyte- in vitro maturation in the patients with malignant tumors undergoing fertility preservation
10.3760/cma.j.cn101441-20221011-00446
- VernacularTitle:卵巢组织卵母细胞体外成熟在恶性肿瘤患者生育力保存中的应用
- Author:
Weie ZHAO
1
;
Peng SUN
1
;
Panyu CHEN
1
;
Yongfang LI
1
;
Jingjie LI
1
;
Haitao ZENG
1
;
Cong FANG
1
;
Xiaoyan LIANG
1
Author Information
1. 中山大学附属第六医院生殖医学研究中心，广州510000
- Publication Type:Journal Article
- Keywords:
Oocytes;
In vitro maturation;
Malignant tumors;
Fertility preservation;
Ovarian tissue cryopreservation
- From:
Chinese Journal of Reproduction and Contraception
2023;43(2):140-144
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the prospects of ovarian tissue oocyte- in vitro maturation (OTO-IVM) in fertility preservation for patients with malignancy. Methods:OTO-IVM outcomes from 27 malignant tumor patients who underwent fertility preservation in Reproductive Medicine Research Center of the Sixth Affiliated Hospital of Sun Yat-Sen University from March 2017 to August 2022 were analyzed, including the number of mature oocytes (M II oocytes), maturation rate, and maturation time. The fertilization rate, the cleavage rate, and the embryonic development potential of IVM-derived M II were also analyzed. Further, the short-term use of gonadotropin (Gn) in OTO-IVM before ovarian tissue acquisition was initially explored. Results:After OTO-IVM, 81.48% (22/27) of patients had at least one M II oocyte, with a mean number of M II oocytes of 3.00 (1.50, 7.00) and a maturation rate of 38.81%. About 4.85% (13/268) of oocytes matured within 24 h; 14.93% (40/268) matured between 24 h and 36 h; 16.79% (45/268) matured between 36 h and 48 h, and only 2.24% (6/268) matured after 48 h. A total of 41 M II oocytes from 4 patients were fertilized by intracytoplasmic sperm injection (ICSI), with a fertilization rate of 85.37% (35/41), cleavage rate of 94.29% (33/35), variable embryo rate of 54.29% (19/35), and high-quality embryo rate of 34.29% (12/35). The IVM rate was significantly higher in patients who used Gn than in those who did not [63.16% (48/76) vs. 29.17% (56/192), P<0.001]. Conclusion:OTO-IVM can be used as a complementary method for fertility preservation in oncology patients and obtain a certain number of oocytes and embryos. Short-term use of Gn before ovarian tissue acquisition can improve oocyte maturation rate, but further studies are needed to verify the value of Gn in OTO-IVM.
